Novavax, Inc.
| Public | |
| Traded as |
NASDAQ: NVAX S&P 500 Component |
| Industry | Biotechnology |
| Founded | 1987 |
| Headquarters | Gaithersburg, Maryland, U.S. |
|
Area served
|
Worldwide |
| Products | Vaccines |
|
Number of employees
|
ca 375 |
| Website | www |
Coordinates: 39°08′14″N 77°13′33″W / 39.1371167°N 77.2258056°W
Novavax, Inc. is a clinical-stage vaccine company headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is a public company that trades under the symbol "NVAX".
In June 2013, Novavax acquired the Matrix-MTMadjuvant platform with the purchase of Swedish company Isconova AB and renamed it Novavax AB.
In 2015 the company received an $89 million grant from the Bill & Melinda Gates Foundation to support the development of a vaccine against human respiratory syncytial virus for infants via maternal immunization.
In March 2015 the company completed a Phase I trial for its Ebola vaccine candidate.
In September 2016 the company announced that a Phase III trial of its RSV vaccine had failed to meet its endpoints, which caused its share price to fall from $8.34 to $1.40 and led the company to lay off 30% of its employees.
As of November 2016 its RSV F vaccine candidate was in three clinical trials.
...
Wikipedia